Register for our free email digests:
Latest From Gelesis Inc.
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
IP commercialization may be all the rage for company creation in the UK, but it remains comparatively unknown in the US. Daphne Zohar of Boston-based PureTech Health talks to START-UP about her firm’s approach to creating and developing life science businesses.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, Research/Analytical, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced April 2015.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced March through April 2015.
- Medical Devices
- Therapeutic Areas
- Metabolic Disorders
- North America
- Parent & Subsidiaries
- Gelesis Inc.
- Senior Management
Yishai Zohar, CEO
Robert Armstrong, CBO
Hassan Heshmati, MD, CMO
- Contact Info
Phone: (617) 482-2333
500 Boylston St., Ste. 1600
Boston, MA 02116
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.